Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain

Figures & data

Table 1. Posology and drug costs for therapies approved for ATTR-PN treatment

Therapy	Dosage (mg)^a	Doses Per Year^a	Cost Per Dose (Ex-factory prices −4% RD)^b,c
Inotersen	284.00 per week	52.18	5,578.47€
Patisiran*	21.26 every 3 weeks	17.39	24,564.69€
Tafamidis	20.00 per day	365.25	355.20€

*Assumes patient weight of 70.87 kg and drug wastage

Source: ^a [17–19]; ^b [20,21]

Table 2. Management costs of AEs related to treatment with inotersen, patisiran, and tafamidis

AE	Cost Per Event^a	AE Probability Per Year (%)
		Inotersen^b	Patisiran^c	Tafamidis^d
Diarrhoea	3835.09€	19.80	26.50	18.30
Extravasation	5560.88€	0.00	0.30	0.00
Infusion-related Reactions	4476.53€	0.00	13.10	0.00
Injection Site Reaction	1610.89€	43.40	0.00	0.00
Peripheral Edema	194.66€	15.30	21.20	4.20
Thrombocytopenia	4341.69€	10.90	0.00	0.00
Upper Abdominal Pain	2311.35€	0.00	0.00	8.40
Urinary tract infection	2478.02€	15.30	8.90	16.06
Vaginal Infection	2968.34€	0.00	0.00	4.20

AE = adverse events

Source: ^a [22]; ^b [13,19]; ^c [12,18]; ^d [11,17].

Table 3. Estimated mean weekly productivity and leisure time loss among patients treated with inotersen, patisiran, and tafamidis

	Absenteeism (Minutes/Week)^a		Leisure (Minutes/Week)^a
	Patient	Caregiver	Patient	Caregiver
Inotersen	186 (3.10 hours)	468 (7.80 hours)	60 (1.00 hour)	90 (1.50 hours)
Patisiran	312 (5.20 hours)	456 (7.60 hours)	330 (5.50 hours)	318 (5.30)
Tafamidis	108 (1.80 hours)	108 (1.80 hours)	36 (0.60 hours)	15 (0.25 hours)

^aSurvey of clinical experts in Spain

Table 4. Total healthcare costs due to treatment with inotersen, patisiran, and tafamidis

	Pre-treatment regimens	Drug acquisition	Administration	Concomitant medications	SOC	AEs	Monitoring	Indirect	TOTAL
Inotersen	0.00€	291,076.46€	0.00€	3.41€	3,109.05€	2,340.43€	996.93€	10,832.02€	308,358.29€
Patisiran	134.99€	427,250.14€*	11,147.60€	3.41€	3,109.05€	1,882.84€	0.00€	15,243.43€	458,771.45€
Tafamidis	0.00€	129,736.80€	0.00€	0.00€	3,109.05€	1,426.98€	0.00€	3,681.10€	137,953.93€

*Assumes patient weight of 70.87 kg

AE = adverse events; SOC = standard of care

Figure 1. Total annual costs among patients treated with inotersen, patisiran, and tafamidis in the base case analysis

Real-Decreto-Ley-8/2010,m.2010. Available from: http://www.boes.es

 Google Scholar

BotPlus. Consejo General de Colegios Oficiales de Farmacéuticos 2020 [cited 2020 Jun 06]. Available at: https://botplusweb.portalfarma.com/

 Google Scholar

[Base de datos de costes sanitarios eSalud]. Barcelona: oblikue consulting, [Internet]. 2020 [cited 2020 Feb 13]. Available at:

 Google Scholar

Benson M, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22–31.

 PubMed Web of Science ®Google Scholar

Summary of Product Characteristics [Internet]. 2018 [cited 2020 Mar 20]. Available at: https://www.ema.europa.eu/en/documents/product-information/tegsedi-epar-product-information_en.pdf

 Google Scholar

Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11–21.

 PubMed Web of Science ®Google Scholar

Summary of Product Characteristics [Internet]. 2018 [cited 2020 Mar 20]. Available at: https://www.ema.europa.eu/en/documents/product-information/onpattro-epar-product-information_en.pdf.

 Google Scholar

Coelho T, Maia LF, Martins Da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012 Aug 21;79(8):785–792.

 PubMed Web of Science ®Google Scholar

Summary of Product Characteristics [Internet]. 2016 [cited 2020 Mar 20]. Available at: https://www.ema.europa.eu/en/documents/product-information/vyndaqel-epar-product-information_en.pdf

 Google Scholar